HOME >> BIOLOGY >> NEWS
Malaria drug may treat metabolic syndrome's many symptoms

A drug used for decades to treat and prevent malaria might also fight the many symptoms of metabolic syndrome, a potentially disabling condition that is estimated to affect as many as a quarter of American adults. The findings appear in the November 2006 issue of the journal Cell Metabolism, published by Cell Press.

Researchers, led by Clay F. Semenkovich of Washington University School of Medicine and Michael B. Kastan of St. Jude Children's Research Hospital, found in studies of mice that the antimalaria drug chloroquine improved symptoms of metabolic syndrome; the drug reduced atherosclerosis, lowered blood pressure, and improved blood sugar tolerance. Chloroquine works by activating a particular stress pathway that mediates susceptibility to the syndrome, they found.

"In animals, activating this pathway with extremely low doses of chloroquine counteracted many of the features of metabolic syndrome," said Semenkovich. Semenkovich said he expects to begin a clinical trial of the drug's utility for curbing metabolic syndrome in human patients very soon.

Often associated with insulin resistance, metabolic syndrome can include five components: high triglycerides, low "good" cholesterol, high blood pressure, high blood sugar, and central obesity--characterized in men by a pants waist size of 40 or greater, Semenkovich said. Patients who exhibit three of the five components fit the criteria for metabolic syndrome.

The condition is also associated with atherosclerosis, leaving patients at increased risk of death from cardiovascular disease, the researchers said.

Rather than representing "a unique entity," some have suggested that the metabolic syndrome may simply reflect the cumulative contribution of its components to atherosclerotic risk, the researchers said. An alternative view is that atherosclerosis, insulin resistance, and the component clinical features of the metabolic syndrome share a common unifying mechanism, t
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
7-Nov-2006


Page: 1 2 3

Related biology news :

1. Malaria -- Effective insecticide-repellent synergy against mosquito vectors
2. Malaria-resistant mosquitoes battle disease with molecular warhead
3. Malaria and Epstein-Barr virus linked to pediatric cancer in Africa
4. Malaria in pregnancy: What can the social sciences contribute?
5. Malaria: The right vaccine in the right place?
6. PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine
7. 20 Years of Malaria Research: Outcomes and Perspectives
8. Malaria poses additional risks for first-time mothers
9. Malaria: Efficacy of monotherapies in Cameroon
10. Malaria, potato famine pathogen share surprising trait
11. Malaria parasite impairs key immune system cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/11/2019)... ... November 11, 2019 , ... MicroGenDX, the world leader in ... in the award-winning study “Next Generation Sequencing for the Diagnosis of Periprosthetic Knee ... processed samples using Next Generation DNA Sequencing to examine the ability of NGS ...
(Date:11/6/2019)... Va. (PRWEB) , ... November 06, 2019 , ... ... today that Donald Stanski, MD, a senior pharmaceutical industry executive with expertise in ... and simulation for drug and disease strategic data analytics, has joined the firm ...
(Date:11/5/2019)... WA (PRWEB) , ... November 05, 2019 , ... ... & Amato Dentistry, providing state-of-the-art cosmetic and restorative dentistry to Seattle, WA, including ... her Doctor of Dental Surgery degree from the University of Washington, Dr. Kopp ...
Breaking Biology News(10 mins):
(Date:11/27/2019)... ... November 25, 2019 , ... Silony Medical, a medical ... and navigated surgery in the UK. The procedure was performed in the UK’s ... Syed Aftab and Dr. Alexander Montgomery. The surgery, which took place on July ...
(Date:11/20/2019)... ... November 20, 2019 , ... Defense and ... microturbine electrical power generation units from 2019-2028. The value of this production is ... of 3,821 units worth $569 million. , Reference to 2017 is important, ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... R&D, today announced that Immatics Biotechnologies , a clinical-stage biopharmaceutical company ... to streamline their R&D operations related to the discovery and development of ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... to educate Americans about the deadly healthcare-associated infection C. diff. The campaign, ... of the epidemic, which kills at least 30,000 people in the U.S. each ...
Breaking Biology Technology:
Cached News: